Physiology of vasopressin relevant to management of septic shock

Chest

Volumn 120, Issue 3, 2001, Pages 989-1002

  Holmes, Cheryl L ^a   Patel, Bhavesh M ^b   Russell, James A ^a   Walley, Keith R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

Adrenergic agents; Antidiuretic hormone; Hypotension; Septic shock; Systemic inflammatory response syndrome; Vasoconstrictor agents; Vasodilation; Vasopressins

Indexed keywords

CORTICOTROPIN; HEMOSTATIC AGENT; HYPERTENSIVE FACTOR; VASOPRESSIN; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ARTERY CONSTRICTION; CARDIOGENIC SHOCK; CLINICAL TRIAL; CORONARY ARTERY DILATATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GIANT CELL; HUMAN; HYPOTENSION; KIDNEY COLLECTING TUBULE; LUNG VASCULAR RESISTANCE; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THERMOREGULATION; URINE VOLUME; VASOCONSTRICTION; VASODILATATION; VASOPRESSIN BLOOD LEVEL; VASOPRESSIN RELEASE;

EID: 0034820482     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.120.3.989     Document Type: Review

References (128)

1. Vasopressin deficiency contributes to the vasodilation of septic shock
2. Vasopressin pressor hypersensitivity in vasodilatory septic shock
3. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis
4. Man and the chimaera: Selective versus neutral oxytocin evolution
5. On the physiological action of extracts of the pituitary body and certain other glandular organs
6. The physiological effects of the hypophysis cerebri and infundibular body
7. Diabete insipido ed opoterapia
8. Die nierenwirkung von hypophysenextrakten beim menshen
9. The secretion of urine as studied on the isolated kidney
10. Pharmacology and clinical perspectives of vasopressin antagonists
11. The purification and the amino acid content of vasopressin preparation
12. A synthetic preparation possessing biological properties associated with arginine-vasopressin
13. Structural bases of vasopressin/oxytocin receptor function
14. Distribution of oxytocin and vasopressin in the rat supraoptic and paraventricular nucleus
15. Osmoregulation of vasopressin neurons: A synergy of intrinsic and synaptic processes
16. Physiological pathways regulating the activity of magnocellular neurosecretory cells
17. Central nervous system mediators of vasopressin release
18. Osmoreceptors, osmoreception, and osmoregulation
19. Syndrome of inappropriate antidiuresis
20. Osmotic and nonosmotic control of vasopressin release
21. Acidemia stimulates ACTH, vasopressin, and heart rate responses in fetal sheep
22. The osmoregulation of vasopressin
23. Influence of volume changes on osmolality-vasopressin relationships in conscious dogs
24. Osmotic control of vasopressin function
25. Control of release of vasopressin by neuroendocrine reflexes
26. Baroreceptor regulation of vasopressin and renin secretion: Low-pressure versus high-pressure receptors
27. Renin and vasopressin responses to graded reductions in atrial pressure in conscious dogs
28. Effects of separate and concurrent osmotic and volume stimuli on plasma ADH in sheep
29. The effects of hypotension and hypovolaemia on the liberation of vasopressin during hemorrhage in the unanaesthetized monkey (Macaca mulatta)
30. Cardiac and arterial baroreceptor influences in release of vasopressin and renin during hemorrhage
31. Response of vasopressin and norepinephrine to lower body negative pressure in humans
32. Arterial pulse pressure and vasopressin release in humans during lower body negative pressure
33. Cardiovascular and endocrine responses to head-up tilt and vasopressin infusion in humans
34. Renin response to stimulation of cardiopulmonary mechanoreceptors in man
35. Effect of moderate hemorrhage in humans on plasma ADH and renin
36. Neurophysiology of body fluid homeostasis
37. Role of nitric oxide in the regulation of renin and vasopressin secretion
38. Opposing α- and β-adrenergic mechanisms mediate dose-dependent actions of norepinephrine on supraoptic vasopressin neurones in vivo
39. 1-Adrenergic receptor activation depolarizes rat supraoptic neurosecretory neurons in vitro
40. Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake
41. A radioimmunoassay for plasma arginine-vasopressin in man and dog: Application to physiological and pathological states
42. Physiologic studies of antidiuretic hormone by its direct measurement in human plasma
43. Metabolism of vasopressin
44. Ventricular receptors stimulate vasopressin release during hemorrhage
45. Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock
46. The secretion and clearance of vasopressin during the development of irreversible hemorrhagic shock
47. Evaluation of cardiac output, total peripheral vascular resistance, and plasma concentrations of vasopressin in the conscious, unrestrained rat during endotoxemia
48. Vasopressin release during sepsis and septic shock in baboons and dogs
49. Prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement
50. Management of vasodilatory shock after cardiac surgery: Identification of predisposing factors and use of a novel pressor agent
51. Intravenous arginine-vasopressin in children with vasodilatory shock after cardiac surgery
52. Vasopressin deficiency and pressor hypersensitivity in hemodynamically unstable organ donors
53. Evidence and quantification of the vasopressin arterial pressure control system in the dog
54. Elevated plasma vasopressin concentrations during endotoxin and E coli shock
55. Role of vasopressin deficiency in the vasodilation of septic shock
56. Spectral analysis of heart rate variability in the sepsis syndrome
57. Vasopressin response to orthostatic hypotension: Etiologic and clinical implications
58. The binding site of neuropeptide vasopressin V1a receptor: Evidence for a major localization within transmembrane regions
59. Signal transduction of V1-vascular vasopressin receptors
60. The cloned vasopressin V1a receptor stimulates phospholipase A2, phospholipase C, and phospholipase D through activation of receptor-operated calcium channels
61. The role of adenosine 3′,5′-phosphate in the action of antidiuretic hormone
62. The human V3 pituitary vasopressin receptor: Ligand binding profile and density-dependent signaling pathways
63. Human vascular endothelial cells express oxytocin receptors
64. Role of vasopressin in blood pressure regulation in conscious water-deprived dogs
65. Role of vasopressin in cardiovascular and blood pressure regulation
66. Greatly enhanced pressor response to antidiuretic hormone in patients with impaired cardiovascular reflexes due to idiopathic orthostatic hypotension
67. Effect of vasopressin blockade on blood pressure regulation during hemorrhage in conscious dogs
68. Blood pressure, pulse, and neurohumoral responses to nitroprusside-induced hypotension in normotensive aging men
69. Vasopressin use in cardiopulmonary resuscitation
70. Interactions of vasopressin with the area postrema in arterial baroreflex function in conscious rabbits
71. Role of V1 receptors in the action of vasopressin on the baroreflex control of heart rate
72. Interaction of vasopressin and the baroreceptor reflex system in the regulation of arterial blood pressure in the dog
73. Cardiac output distribution during vasopressin infusion or dehydration in conscious dogs
74. Role of nitric oxide in the cerebral vasodilatory responses to vasopressin and oxytocin in dogs
75. Vasopressin induces endothelium-dependent relaxations of cerebral and coronary, but not of systemic arteries
76. Changes of vascular reactivity induced by low vasopressin concentrations: Interactions with cortisol and lithium and possible involvement of prostaglandins
77. Potentiation by vasopressin of adrenergic vasoconstriction in the rat isolated mesenteric artery
78. Role of vasopressin on adrenergic neurotransmission in human penile blood vessels
79. Vasopressin modulates K(+)-channel activities of cultured smooth muscle cells from porcine coronary artery
80. Physiological roles and properties of potassium channels in arterial smooth muscle
81. The ATP-sensitive K+ channel mediates hypotension in endotoxemia and hypoxic lactic acidosis in dog
82. Dose-response relationships for arginine vasopressin and synthetic analogs on three types of rat blood vessels: Possible evidence for regional differences in vasopressin receptor sites within a mammal
83. Endoscopic demonstration that vasopressin but not propranolol produces gastric mucosal ischemia in dogs with portal hypertension
84. Effect of vasopressin on regional splanchnic blood flows in conscious man
85. Vascular effects of vasopressin an oxytocin in the pig mesenteric bed
86. Effects of vasopressin on cardiac output and its distribution in the subhuman primate
87. Effects of vasopressin on portal hemodynamics in patients with portal hypertension
88. cAMP and extrarenal vasopressin V2 receptors in dogs
89. Role of vasopressin in the cardiovascular response to hypoxia in the conscious rat
90. Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries
91. Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries
92. Regional differences in the vasodilator response to vasopressin in canine cerebral arteries in vivo
93. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus
94. Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles
95. Vasopressin lowers pulmonary artery pressure in hypoxic rats by releasing atrial natriuretic peptide
96. Vasopressin-induced pulmonary vasodilation in rats
97. Enhanced pulmonary arterial dilation to arginine vasopressin in chronically hypoxic rats
98. Effects of vasopressin on pulmonary and systemic vascular mechanics
99. Role of nitric oxide in vasopressinergic pulmonary vasodilatation
100. Comparison of responses of canine pulmonary artery and vein to angiotensin II, bradykinin and vasopressin
101. Arginine vasopressin induces endothelium-dependent vasodilatation of the pulmonary artery: V1-receptor-mediated production of nitric oxide
102. Desensitization of vasopressin sensitive adenylate cyclase by vasopressin and phorbol esters
103. Renal microvascular effects of vasopressin and vasopressin antagonists
104. Effect of infusion of pharmacologic amounts of vasopressin on renal electrolyte excretion
105. Conformation considerations of vasopressin as a guide to development of biological probes and therapeutic agents
106. Arginine vasopressin-induced renal vasodilation mediated by nitric oxide
107. Dose-response effects of pressor doses of arginine vasopressin on renal hemodynamics in the rat
108. Vasopressin activates collecting duct urea transporters and water channels by distinct physical processes
109. Renal cortical and medullary blood flow responses during water restriction: Role of vasopressin
110. Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure
111. Vasopressin in the treatment of milrinone-induced hypotension in severe heart failure
112. Juxtamedullary microvascular responses to arginine vasopressin in rat kidney
113. Vasopressin in the evaluation of pituitary-adrenal function
114. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age
115. Role of nitric oxide in the vasopressin-induced corticosterone secretion in rats
116. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin
117. Aggregation of human blood platelets by vasopressin
118. Response of factor VIII/von Willebrand factor to DDAVP in healthy subjects and patients with hemophilia A and von Willebrand's disease
119. Arginine vasopressin as a central neurotransmitter
120. Circadian variation of plasma arginine vasopressin concentration, or arginine vasopressin in enuresis
121. Beneficial treatment of age-related sleep disturbances with prolonged intranasal vasopressin
122. Central arginine vasopressin and endogenous antipyresis
123. Vasopressin and central integrative processes
124. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation
125. The role of vasopressin in the maintenance of cardiovascular function during early endotoxin shock
126. Plasma vasopressin levels during hemorrhage in mature and immature fetal sheep
127. Low-dose vasopressin in the treatment of vasodilatory septic shock
128. Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock